Edition:
United States

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

3,827.00GBp
11:39am EDT
Change (% chg)

7.00 (+0.18%)
Prev Close
3,820.00
Open
3,900.00
Day's High
3,918.50
Day's Low
3,798.00
Volume
5,330,205
Avg. Vol
3,940,748
52-wk High
5,021.00
52-wk Low
2,940.50

Chart for

About

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas... (more)

Overall

Beta: 1.50
Market Cap(Mil.): £35,955.00
Shares Outstanding(Mil.): 911.87
Dividend: 21.46
Yield (%): --

Financials

  SHP.L Industry Sector
P/E (TTM): 26.40 29.67 32.21
EPS (TTM): 1.45 -- --
ROI: 3.09 13.44 13.05
ROE: 5.66 15.16 14.90

Overshadowed by Takeda bid, Shire reports solid start to year

LONDON London-listed drugmaker Shire reported a solid start to the year on Thursday with first-quarter earnings up 6 percent despite challenges on several fronts as it works towards a deal to be acquired by Takeda Pharmaceutical .

10:39am EDT

UPDATE 2-Overshadowed by Takeda bid, Shire reports solid start to year

* Q1 revenue up 5 pct, earnings up 6 pct beat market forecasts

10:36am EDT

BRIEF-Shire declines to comment on Takeda, any further disposals

* CEO SAYS REMAINS CONFIDENT IN OUTLOOK AND GUIDANCE FOR HEMATOLOGY FRANCHISE

7:57am EDT

Bid target Shire reports 6 pct rise in first-quarter earnings

LONDON, April 26 Shire, the London-listed drugmaker targeted by Takeda Pharmaceutical, reported a 6 percent rise in first-quarter earnings on Thursday, helped by higher product sales and a lower tax rate partially offset by lower gross margins.

7:14am EDT

Deals of the day-Mergers and acquisitions

April 25 The following bids, mergers, acquisitions and disposals were reported by 2231 GMT on Wednesday:

Apr 25 2018

Shire willing to back $64 billion Takeda bid, market signals doubts

LONDON/NEW YORK/TOKYO Rare disease specialist Shire said on Wednesday it was willing to recommend a sweetened $64 billion offer from Japan's Takeda Pharmaceutical Co to shareholders, in what would be the biggest acquisition of a drug company since 2000. | Video

Apr 25 2018

UPDATE 10-Shire willing to back $64 bln Takeda bid, market signals doubts

* Takeda shares down 7 pct, Shire off 2.8 pct (Adds Shire shares closing down, more on pharma industry M&A)

Apr 25 2018

GSK rules out entering Shire takeover battle

LONDON GlaxoSmithKline's chief executive said on Wednesday she had no interest in acquiring Shire , the London-listed rare diseases specialist that Takeda Pharmaceutical hopes to buy for some $64 billion.

Apr 25 2018

GSK rules out entering Shire takeover battle

LONDON, April 25 GlaxoSmithKline's chief executive said on Wednesday she had no interest in acquiring Shire, the London-listed rare diseases specialist that Takeda Pharmaceutical hopes to buy for some $64 billion.

Apr 25 2018

Shire bid marks Takeda's latest - and biggest - push for global status

TOKYO Takeda Pharmaceutical Co Ltd's $64 billion bid for London-listed rare disease specialist Shire Plc bolsters its credentials as Japan's most outward facing drugs firm, a mould-breaking image that has been more than a decade in the making.

Apr 25 2018

Earnings vs. Estimates